ImClone chairman hits back at Icahn as tempers rise
613582
ImClone Systems Inc.'s  chairman  lashed out on Thursday at the company's newest board member,  billionaire investor Carl Icahn, in what looks set to become a  bitter feud at a time the company can least afford it.
71455
'This will hurt you more than it hurts me' Oracle let its $17 per share offer for BEA lapse yesterday, but activist investor Carl Icahn has demanded the middleware firm put the offer to shareholders anyway.â¦
272040
Billionaire investor Carl Icahn and a group of investors are opposing yet another corporate takeover. The investors, led by Icahn, have accumulated a 7 percent stake in Mylan Laboratories Inc.
321927
Mylan Laboratories&#39; (MYL:NYSE - news - research) board of directors Monday once again rejected investor Carl Icahn&#39;s takeover offer while also questioning his intentions and said it planned to go ahead with its planned acquisition of King Pharmaceuticals
230724
Former marketing executive, in a legal battle, accuses the companyâs chief of violating its policies.
568863
BEA Systems replied Monday to investor Carl Icahn&#39;s demand for a shareholder vote on purchase bids for the company.
720317
Billionaire activist investor Carl Icahn on Friday called for the sale of BEA Systems Inc., a business software maker whose stock price has sagged with the growth in open-source software and under pressure from larger competitors such as IBM Corp. and Oracle Corp.
260832
BOSTON  â The investor Carl C. Icahn said on Monday that he was trying to get three supporters elected to the board of the biotechnology firm Biogen Idec because of concerns over the sales process.
254001
Billionaire investor Carl Icahn, who is pressing for board changes at biotechnology company ImClone Systems Inc. , on Wednesday acknowledged that he rejected $36-per-share takeover offer for the company, saying the company is worth more.
502255
Company urges shareholders not to sign proxy cards for billionaire Carl Icahn, who wants a seat on Motorola's board.
205093
Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) on Monday said its board does not believe discussions with financier Carl Icahn&#39;s about his unsolicited proposal to buy the company are in the company&#39;s best interests.
107025
Mylan Laboratories Inc. continued to insist Monday that its $4 billion acquisition of King Pharmaceuticals Inc. was in the company&#39;s best interest, following a meeting last week with Carl Icahn, who opposes the deal.
165524
Mylan Laboratories Inc. was one of the few drug makers whose stock closed up Friday with the sector down for a second day as fresh squabbles between veteran financier Carl Icahn and the company&#39;s board erupted.
94977
Mylan Laboratories Inc.&#39;s board Monday shunned an overture by financier Carl Icahn and said the company intends to remain independent while pursuing its proposed acquisition of King Pharmaceuticals, which Icahn opposes.
769283
The German co-chief executive of the European Aeronautic Defence and Space Co. on Wednesday criticized the French for failing to resolving a leadership fight over the company more quickly.
131803
The founder of a firm which shut two factories and cut 420 jobs attacks critics, including the first minister.
768811
After shooing away Oracle Corp.'s $6.7 billion takeover bid, business software maker BEA Systems Inc. dug in its heels for a potentially disruptive battle with its largest shareholder, activist investor Carl Icahn.